Newsroom

MAY 23, 2019 Glytec Goes Global, With Six New International Patent Allowances The digital therapeutics pioneer is expanding its intellectual property footprint beyond the U.S., gaining worldwide protections for its proprietary diabetes therapy management solutions. Waltham, MA — The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated...

MAY 16, 2019 Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies The company’s growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care. Waltham, MA — Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by...

APRIL 9, 2019 Glytec Receives Another Patent Allowance for Therapy Advisor® The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications. Waltham, MA — The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy...

NOVEMBER 28, 2018 Glytec to Host Webinar in Partnership with American Hospital Association: Improving the Quality and Cost of Diabetes Care The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health. Waltham, MA — The population of hospitalized...

OCTOBER 30, 2018 Glytec publishes free eBook: Hypoglycemia in the hospital. Why is it costing you millions and what can you do? The popular eBook showcases clinical and financial implications of hypoglycemia, a common occurrence among hospitalized patients that costs the average hospital $1.5 to $5.6 million a year, or more. Waltham, MA — Hypoglycemia in the hospital is common, costly, extremely...

AUGUST 29, 2018 Glytec Receives Two More Patent Allowances for its Insulin Optimization System The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting. Waltham, MA — The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive...

MARCH 28, 2018 Two More Patent Allowances for Glytec’s Diabetes Software The latest allowances from the USPTO address systems and methods specific to the dosing of subcutaneous insulin for acute and chronic care. Waltham, MA — The United States Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec’s FDA-cleared proprietary software used by healthcare providers to...

JANUARY 9, 2018 USPTO Grants Glytec Patent Allowance for Computer-Guided Selection and Dosing of All Diabetes Medications The new patent allowance addresses personalized optimization of insulin and non-insulin medications alike. Waltham, MA — Long recognized as the market leader in enterprise software solutions for insulin management, Glytec is expanding its intellectual property protections...

JANUARY 5, 2018 Glytec Awarded Patent Allowance Supporting Connected Care Model for Insulin Management The allowed patent encompasses detailed interactions between multiple connected diabetes technologies. Waltham, MA — Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient...

AUGUST 16, 2017 Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software The company’s eGlycemic Management System® featuring Glucommander™ has the broadest indications for use of any decision support solution for insulin titration. WALTHAM, MA — The pioneer of diabetes therapy management software, Glytec announces its fourth FDA clearance, adding...